Abstract:BackgroundPathological cardiac hypertrophy occurs in response to numerous stimuli and precedes heart failure (HF). Therapies that ameliorate pathological cardiac hypertrophy are highly needed.MethodsThe expression level of miR-30d was analyzed in hypertrophy models and serum of patients with chronic heart failure by qRT-PCR. Gain and loss-of-function experiments of miR-30d were performed in vitro. miR-30d gain of function were performed in vivo. Bioinformatics, western blot, luciferase assay, qRT-PCR, and immunofluorescence were performed to examine the molecular mechanisms of miR-30d.FindingsmiR-30d was decreased in both murine and neonatal rat cardiomyocytes (NRCMs) models of hypertrophy. miR-30d overexpression ameliorated phenylephrine (PE) and angiotensin II (Ang II) induced hypertrophy in NRCMs, whereas the opposite phenotype was observed when miR-30d was downregulated. Consistently, the miR-30d transgenic rat was found to protect against isoproterenol (ISO)-induced pathological hypertrophy. Mechanistically, methyltransferase EZH2 could promote H3K27me3 methylation in the promotor region of miR-30d and suppress its expression during the pathological cardiac hypertrophy. miR-30d prevented pathological cardiac hypertrophy via negatively regulating its target genes MAP4K4 and GRP78 and inhibiting pro-hypertrophic nuclear factor of activated T cells (NFAT). Adeno-associated virus (AAV) serotype 9 mediated-miR-30d overexpression exhibited beneficial effects in murine hypertrophic model. Notably, miR-30d was reduced in serum of patients with chronic heart failure and miR-30d overexpression could significantly ameliorate pathological hypertrophy in human embryonic stem cell-derived cardiomyocytes.InterpretationOverexpression of miR-30d may be a potential approach to treat pathological cardiac hypertrophy.FundingThis work was supported by the grants from National Key Research and Development Project (2018YFE0113500 to J Xiao), National Natural Science Foundation of China (82020108002 to J Xiao, 81900359 to J Li), the grant from Science and Technology Commission of Shanghai Municipality (20DZ2255400 and 21XD1421300 to J Xiao, 22010500200 to J Li), Shanghai Sailing Program (19YF1416400 to J Li), the “Dawn” Program of Shanghai Education Commission (19SG34 to J Xiao), the “Chen Guang” project supported by the Shanghai Municipal Education Commission and Shanghai Education Development Foundation (19CG45 to J Li).

miR‐31‐5p suppresses myocardial hypertrophy by targeting Nfatc2ip

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

Silencing N29 Regulated miR‐193b‐5p/TGFBR2 Axis to Mitigate the Progression of Cardiac Hypertrophy

Cardiac Hypertrophy is Positively Regulated by MicroRNA-24 in Rats

Mir-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy

Microrna-340-5p Functions Downstream Of Cardiotrophin-1 To Regulate Cardiac Eccentric Hypertrophy And Heart Failure Via Target Gene Dystrophin

Mir-139-5p Inhibits Isoproterenol-Induced Cardiac Hypertrophy by Targetting C-Jun

Regulatory Effects of miRNA-31 on LATS2 and Cardiomyocyte Hypertrophy in Rat's Cardiomyocytein vitro

Myocyte-specific Enhancer Factor 2C: a Novel Target Gene of Mir-214-3p in Suppressing Angiotensin II-induced Cardiomyocyte Hypertrophy.

Mir-96 Inhibits Cardiac Hypertrophy by Targeting Growth Factor Receptor-Bound 2.

Mechanism of Cardiac Hypertrophy Regulates by miR-30e

Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a

Long Noncoding RNA Myocardial Infarction‑associated Transcript is Associated with the Microrna‑150‑5p/p300 Pathway in Cardiac Hypertrophy.

Microrna-327 Regulates Cardiac Hypertrophy And Fibrosis Induced By Pressure Overload

Mir-218 Involvement in Cardiomyocyte Hypertrophy is Likely Through Targeting Rest

MicroRNA-101 Inhibits Rat Cardiac Hypertrophy by Targeting Rab1a.

MiR-100-5p Regulates Cardiac Hypertrophy Through Activation of Autophagy by Targeting Mtor.

Overexpression of macrophage migration inhibitory factor protects against pressure overload-induced cardiac hypertrophy through regulating the miR-29b-3p/HBP1 axis

CDK6 Mediates the Effect of Attenuation of Mir-1 on Provoking Cardiomyocyte Hypertrophy

Targeting Mir-30D Reverses Pathological Cardiac Hypertrophy

mir15a/mir16‐1 cluster and its novel targeting molecules negatively regulate cardiac hypertrophy